ClinicalTrials.gov
Cure8 trial brief
Why This Matters
A new oral investigational drug (HRS-7085) is entering early human testing for moderate-to-severe ulcerative colitis. People with UC who have not benefited from approved therapies may be interested in trial options and safety data that will come from this study.
Who Should Pay Attention
Adults with moderate-to-severe ulcerative colitis; clinicians and researchers; patients with prior biologic or JAK-inhibitor exposure
Study Snapshot
Story typeClinical Reference
Trial phasePhase 1
Enrollment8 participants
Study statusNot_yet_recruiting
Source depthTrial registry record
What To Know
ClinicalTrials.gov lists a Phase 1 interventional study of HRS-7085 tablets in adults with moderate to severe ulcerative colitis that is not yet recruiting. The trial will evaluate safety, tolerability, and pharmacokinetics and plans to randomize participants to HRS-7085 or placebo for 12 weeks, with adverse events recorded as a primary outcome at Week 12.
The registry entry specifies detailed eligibility criteria: adults 18–75 with a modified 9‑point Mayo score of 5–9 and endoscopic subscore 2–3, prior inadequate response or intolerance to conventional therapies or biologics/JAK inhibitors, and stable background UC medications in specified windows.
The planned enrollment is small (n=8) and the study is Phase 1, focused on early safety and PK rather than efficacy.
Keep In Mind
Phase 1 trials are primarily designed to measure safety and pharmacokinetics in a small number of participants; efficacy is not the main objective. The study is registered as not yet recruiting and lists strict eligibility and washout criteria.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorJiangsu HengRui Medicine Co., Ltd.
Trial IDNCT07760831
Study typeInterventional
Trial phasePhase 1
Enrollment8 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedAug 12, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A Case of Elderly-Onset Ulcerative Colitis with Large-Vessel Giant Cell Arteritis Treated Successfully with Tofocitinib.
Older adults with ulcerative colitis can rarely develop large-vessel giant cell arteritis as an extraintestinal complication.
Study of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis
This study will collect real-world data on adults with moderate-to-severe ulcerative colitis who start upadacitinib, tracking symptom remission and imaging response over one to two years — information that can help...
Effectiveness of tofacitinib as rescue therapy in biological-naive patients with steroid-refractory acute severe ulcerative colitis: a multicentric retrospective analysis.
This study suggests tofacitinib may work quickly as a rescue option for biologic‑naive patients with steroid‑refractory ASUC and that many achieved steroid‑free remission by 24 weeks — information that could matter when...